Markets:

Overview

News

Currencies

International

Treasuries

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Deciphera Pharmaceuticals Stock Jumped This Week ↗

March 16, 2023

The company's lead therapy received an FDA Breakthrough Therapy designation.

Via The Motley Fool

Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space ↗

March 16, 2023

Via Benzinga

Where Deciphera Pharmaceuticals Stands With Analysts ↗

March 15, 2023

Via Benzinga

Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗

February 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Looking Into Deciphera Pharmaceuticals's Return On Capital Employed ↗

February 08, 2023

Via Benzinga

Earnings Outlook For Deciphera Pharmaceuticals ↗

February 06, 2023

Via Benzinga

The Latest Analyst Ratings for Deciphera Pharmaceuticals ↗

January 25, 2023

Via Benzinga

Deciphera Pharmaceuticals's Return On Capital Employed Insights ↗

November 22, 2022

Via Benzinga

Deciphera Earns Price Target Bump With Encouraging ESMO Presentation ↗

September 12, 2022

Via Benzinga

$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying ↗

January 25, 2023

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

Via Benzinga

Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 19, 2023

Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.

Via Benzinga

Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low ↗

January 19, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday.

Via Benzinga

Why Deciphera Pharmaceuticals Stock Is Nosediving ↗

January 19, 2023

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock.

Via Benzinga

Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket ↗

January 19, 2023

Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.

Via Benzinga

Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 19, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 04, 2023

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗

January 06, 2023

Via Benzinga

Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday ↗

January 04, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗

January 04, 2023

Via Benzinga

Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients ↗

January 04, 2023

Via Benzinga

Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies ↗

December 14, 2022

Via Benzinga

Deciphera Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2022

Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For Deciphera Pharmaceuticals ↗

November 02, 2022

Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Where Deciphera Pharmaceuticals Stands With Analysts ↗

September 27, 2022

Over the past 3 months, 7 analysts have published their opinion on Deciphera Pharmaceuticals (NASDAQ:DCPH) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

McDonald's Price Target Cut By This Analyst, Plus Cowen Predicts $362 For Domino's Pizza ↗

September 27, 2022

Citigroup cut McDonald's Corporation (NYSE: MCD) price target from $275 to $246. McDonald's shares rose 0.5% to $245.00 in pre-market trading.

Via Benzinga

SVB Leerink Maintains Outperform Rating for Deciphera Pharmaceuticals: Here's What You Need To Know ↗

September 12, 2022

SVB Leerink has decided to maintain its Outperform rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) and raise its price target from $21.00 to $25.00. Shares of Deciphera Pharmaceuticals are trading up...

Via Benzinga

This Analyst Slashes PT On Meta Platforms, Plus Mizuho Predicts $440 For Adobe ↗

September 12, 2022

Mizuho cut the price target for Adobe Inc (NASDAQ: ADBE) from $480 to $440. Adobe shares fell 1.3% to $389.82 in pre-market trading.

Via Benzinga

Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday ↗

September 12, 2022

Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock....

Via Benzinga

4 Analysts Have This to Say About Deciphera Pharmaceuticals ↗

August 29, 2022

Within the last quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 ↗

August 29, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

Headline News about Deciphera Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today